|3D Bioprinter by Organovo|
|Cross-section of multi-cellular bioprinted human liver tissue|
Using research and patents developed by Dr. Gabor Forgacs at the University of Missouri, Organovo is on the verge of releasing a product that uses 3D bioprinting to create a Human Liver System that can detect toxicity in potential new drugs. By detecting toxicity earlier, the Human Liver System reduces the risks of introducing dangerous drugs and saves the expense of testing in live patients.
While the first applications for Organovo's bioprinting are drug testing, the company believes that "engineered tissues will someday be a routine source of therapy for patients with damages or diseased tissue. Using bioprinted organ patches made from the patient's own cells could prevent transplant rejection and the need for immunosuppresant drugs.
Organovo's scientific founder, Gabor Forgacs, presents on bioprinting at TEDMED.
You might also like: